Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study.

Autor:	Yildirim HC; Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.; Department of Medical Oncology, Nigde Research and Education Hospital, Nigde, Turkey., Kapar C; Department of Medical Oncology, Bakırkoy Dr. Sadi Konuk Education and Research Hospital, İstanbul, Turkey., Koksal B; Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey., Seyyar M; Department of Medical Oncology, Kocaeli University Faculty of Medicine, Kocaeli, Turkey., Sanci PC; Department of Medical Oncology, Kocaeli University Faculty of Medicine, Kocaeli, Turkey., Guliyev M; Department of Medical Oncology, Istanbul Cerrahpasa University Faculty of Medicine, Istanbul, Turkey., Perkin P; Department of Medical Oncology, Yildirim Beyazit University, Bilkent State Hospital, Ankara, Turkey., Buyukkor M; Department of Medical Oncology, Dr. A. Y. Ankara Oncology Research and Education Hospital, University of Health Sciences, Ankara, Turkey., Yaslikaya S; Department of Medical Oncology, Cukurova University Faculty of Medicine, Adana, Turkey., Majidova N; Department of Medical Oncology, Marmara University Faculty of Medicine, Istanbul, Turkey., Keskinkilic M; Department of Medical Oncology, 9 Eylül University Faculty of Medicine, Izmir, Turkey., Ozaskin D; Department of Medical Oncology, Afyon Health Sciences University School of Medicine, Afyonkarahisar, Turkey., Avci T; Department of Medical Oncology, Celal Bayar University Faculty of Medicine, Manisa, Turkey., Gunes TK; Department of Medical Oncology, Umraniye Research and Education Hospital, Istanbul, Turkey., Arcagok M; Department of Medical Oncology, Dicle University Faculty of Medicine, Diyarbakir, Turkey., Topal A; Department of Medical Oncology, University of Health Sciences, Gulhane School of Medicine, Ankara, Turkey., Keskin GSY; Department of Medical Oncology, University of Health Sciences, Gulhane School of Medicine, Ankara, Turkey., Kavgaci G; Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey., Yildirim N; Department of Medical Oncology, Firat University Faculty of Medicine, Elazig, Turkey., Celayir OM; Department of Medical Oncology, Acibadem University Faculty of Medicine, Istanbul, Turkey., Avci N; Department of Medical Oncology, Medicana Hospital, Bursa, Turkey., Aslan F; Department of Medical Oncology, Medical Park Ankara Hospital, Ankara, Turkey., Alkan A; Department of Medical Oncology, Mugla Sitki Kocman University Faculty of Medicine, Mugla, Turkey., Erciyestepe M; Department of Medical Oncology, Istanbul Prof. Dr. Cemil Tascioglu State Hospital, Istanbul, Turkey., Cengiz M; Department of Medical Oncology, Erciyes University Faculty of Medicine, Kayseri, Turkey., Pehlivan M; Department of Medical Oncology, Zonguldak Ataturk State Hospital, Zonguldak, Turkey., Gulmez A; Department of Medical Oncology, Adana City Education and Research Hospital, Adana, Turkey., Beypinar I; Department of Medical Oncology, Alaaddin Keykubat University Faculty of Medicine, Antalya, Turkey., Basoglu Tuylu T; Department of Medical Oncology, Nigde Research and Education Hospital, Nigde, Turkey., Kayikcioglu E; Department of Medical Oncology, Isparta Suleyman Demirel University Faculty of Medicine, Isparta, Turkey., Chalabiyev E; Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey., Turhal S; Department of Medical Oncology, Anadolu Health Center, Istanbul, Turkey., Guzel HG; Department of Medical Oncology, Antalya Education and Research Hospital, Antalya, Turkey., Ayas E; Department of Medical Oncology, Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey., Sahbazlar M; Department of Medical Oncology, Celal Bayar University Faculty of Medicine, Manisa, Turkey., Dulgar O; Department of Medical Oncology, Umraniye Research and Education Hospital, Istanbul, Turkey., Demir H; Department of Medical Oncology, Afyon Health Sciences University School of Medicine, Afyonkarahisar, Turkey., Yavuzsen T; Department of Medical Oncology, 9 Eylül University Faculty of Medicine, Izmir, Turkey., Bayoglu V; Department of Medical Oncology, Marmara University Faculty of Medicine, Istanbul, Turkey., Kivrak Salim D; Department of Medical Oncology, Antalya Education and Research Hospital, Antalya, Turkey., Ozturk B; Department of Medical Oncology, Antalya Education and Research Hospital, Antalya, Turkey., Ozdemir F; Department of Medical Oncology, Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey., Kara O; Department of Medical Oncology, Cukurova University Faculty of Medicine, Adana, Turkey., Oksuzoglu B; Department of Medical Oncology, Dr. A. Y. Ankara Oncology Research and Education Hospital, University of Health Sciences, Ankara, Turkey., Bal O; Department of Medical Oncology, Yildirim Beyazit University, Bilkent State Hospital, Ankara, Turkey., Demirci NS; Department of Medical Oncology, Istanbul Cerrahpasa University Faculty of Medicine, Istanbul, Turkey., Yilmaz M; Department of Medical Oncology, Bakırkoy Dr. Sadi Konuk Education and Research Hospital, İstanbul, Turkey., Cabuk D; Department of Medical Oncology, Kocaeli University Faculty of Medicine, Kocaeli, Turkey., Aksoy S; Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
Jazyk:	angličtina
Zdroj:	Journal of chemotherapy (Florence, Italy) [J Chemother] 2024 Mar 18, pp. 1-7. Date of Electronic Publication: 2024 Mar 18.
DOI:	10.1080/1120009X.2024.2330835
Abstrakt:	The only phase 3 study on the effectiveness of CDK 4-6 inhibitors in first-line treatment in premenopausal patients with hormone receptor (HR) positive, HER2 negative metastatic breast cancer is the MONALEESA-7 study, and data on the effectiveness of palbociclib is limited. Data are also limited regarding the effectiveness of CDK 4-6 inhibitors in patients whose dose was reduced due to neutropenia, the most common side effect of CDK 4-6 inhibitors. In our study, we aimed to evaluate the effectiveness of palbociclib and ribociclib in first-line treatment in patients with premenopausal metastatic breast cancer and the effect of dose reduction due to neutropenia on progression-free survival. Our study is a multicenter, retrospective study, and factors affecting progression-free survival (PFS) were examined in patients diagnosed with metastatic premenopausal breast cancer from 29 different centers and receiving combination therapy containing palbociclib or ribociclib in the metastatic stage. 319 patients were included in the study. The mPFS for patients treated with palbociclib was 26.83 months, and for those receiving ribociclib, the mPFS was 29.86 months ( p  = 0.924). mPFS was 32.00 months in patients who received a reduced dose, and mPFS was 25.96 months in patients who could take the initial dose, and there was no statistical difference ( p  = 0.238). Liver metastasis, using a fulvestrant together with a CDK 4-6 inhibitor, ECOG PS 1 was found to be a negative prognostic factor. No new adverse events were observed. In our study, we found PFS over 27 months in patients diagnosed with premenopausal breast cancer with CDK 4-6 inhibitors used in first-line treatment, similar to post-menopausal patients. We did not detect any difference between the effectiveness of the two CDK 4-6 inhibitors, and we showed that there was no decrease in the effectiveness of the CDK 4-6 inhibitor in patients whose dose was reduced due to neutropenia.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu